Lonza expands its long-term manufacturing partnership with Genetix to increase production capacity for ZYNTEGLO gene therapy to meet rising demand in transfusion-dependent beta-thalassemia.
Written By: Marka Sheshi, PharmD
Reviewed By: Pharmacally Editorial Team
Lonza and Genetix Biotherapeutics have expanded their long-term commercial manufacturing agreement to support increasing global demand for the gene therapy ZYNTEGLO, the only FDA-approved treatment for pediatric and adult patients with transfusion-dependent beta-thalassemia.
The renewed agreement builds on a strategic partnership that began in 2013 and ultimately supported the therapy’s commercial approval in 2022.
Under the extended collaboration, Lonza will increase manufacturing capacity for ZYNTEGLO to ensure a reliable supply as patient demand continues to grow.
Commercial production will remain at Lonza’s cell and gene therapy manufacturing facility in Houston, United States. The site has nearly a decade of combined clinical and commercial experience supporting the manufacture of the therapy and will serve as the primary hub for scaling production. The agreement also includes provisions to further expand manufacturing capacity to support additional future therapies from Genetix.
Daniel Palmacci, Head of Specialized Modalities at Lonza, said the extended partnership reflects the company’s expertise in commercial cell and gene therapy manufacturing. He noted that expanding production of ZYNTEGLO at the Houston facility will help meet increasing demand while maintaining high manufacturing standards.
Brian Riley, President and Chief Technology Officer at Genetix, highlighted the importance of Lonza’s role in ensuring consistent supply of the therapy. He stated that the collaboration combines scientific rigor, quality focus, and operational reliability, which have been critical in supporting the commercial rollout of ZYNTEGLO.
According to the company, demand for Genetix’s therapies has grown steadily over the past year. Expanding manufacturing capacity through the Lonza partnership is expected to strengthen supply and support the company’s broader long-term manufacturing strategy as it continues to develop gene therapies for severe rare diseases such as transfusion-dependent beta-thalassemia.
References
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™, 09 March 2026, Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for…
About the Writer
Marka Sheshi | Doctor of Pharmacy
Driven by a deep commitment to clinical excellence, research integrity, and impactful medical writing. With a strong foundation in pharmacotherapy and patient safety, specializes in transforming complex scientific evidence into authoritative, publication-ready content. Passionate about advancing healthcare through precise, evidence-based communication that informs practice, strengthens research visibility, and improves patient outcomes.